VANCOUVER, British Columbia, Nov. 01, 2019 (GLOBE NEWSWIRE) -- RavenQuest BioMed Inc. (CSE: RQB OTCQB: RVVQF Frankfurt: 1IT) (the “Company” or “RavenQuest”), one of Canada’s most innovative cannabis companies, announces that Mark Percival and Mark Ahrens-Townsend have been elected as directors of the Company at its annual general meeting held on October 30, 2019. Further information on each can be found below. Messrs. Percival and Ahrens-Townsend fill the vacancies created by Chris Bechtel and Dr. Jorge Bonet, who did not stand for re-election at the meeting.
“As RavenQuest continues to lead the industry as an innovator among cannabis companies, it is important that the composition, experience and expertise of our board continues to align with the Company's strategic direction,” said George Robinson, CEO of RavenQuest. “I’m confident that the changes announced today will ensure our board will continue to provide robust oversight and leadership as we embark upon the production era of our growing company,” Robinson continued.
“RavenQuest wishes to thank Mr. Bechtel and Dr. Bonet for their contribution to the Company. During our early days as a public entity, both gentlemen were key contributors in guiding our company through the many accomplishments it has made to this point,” stated Robinson.
Dr. Mark Percival is the CEO of Nanosphere Health Sciences Inc. and the owner of Health Coach Systems International Inc. He has been a progressive health professional and clinician for 33 years. He has also been a corporate executive and co-founder of seven companies in the healthcare industry over the last 24 years. His experience compelled him to create the first health coach company, Health Coach Systems International Inc. Founded in the late 80's, Health Coach continuously challenged status quo in healthcare. Mark's leadership and progressive approach led to international recognition and roles in companies willing to challenge the status quo and advance healthcare in important areas. In his role as CEO of Health Coach Systems International Inc. Mark continued his work through consulting on advancements in healthcare, augmenting human performance and mitigating and preventing preventable illness. This led to his study of medical cannabis and related technology. He subsequently became an investor in the Corporation and the CEO of Nanosphere Health Sciences Inc, an emerging publicly-traded nano-biotechnology company.
Mr. Mark Ahrens-Townsend has spent over 35 years in the technology, engineering and venture capital industries. For the past 25 years he has held senior executive roles and has served as President and CEO of three Canadian-based publicly traded companies specializing in information, communication and bio technology. His business experience spans North America, Europe and Asia. In addition, he has also served extensively on the boards and committees of several private and publicly held companies. Mr. Ahrens-Townsend holds a B.Sc. (Engineering) and an MBA (Finance) from the University of Manitoba.
For more information, access RavenQuest’s investor presentation, fact sheet and videos here.
About RavenQuest BioMed Inc.
RavenQuest is a diversified publicly traded cannabis company with divisions focused upon cannabis production, management services & consulting and specialized research & development. RavenQuest is a licensed producer with facilities located in Markham, Ontario and Edmonton, Alberta.
RavenQuest maintains a research partnership with McGill University focused upon cultivar (strain) recognition, plant stabilization and yield maximization of the cannabis plant. The Company also focuses on partnerships with Indigenous communities.
On Behalf of the Board of Directors of
RAVENQUEST BIOMED INC.
Chief Executive Officer
|For further information, please contact:||Mathieu McDonald, Corporate Communications|
Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this press release, which has been prepared by management.
Cautionary Note Regarding Forward-Looking Statement
All statements in this press release, other than statements of historical fact, are “forward-looking information” with respect to the Company within the meaning of applicable securities laws. The Company provides forward-looking statements for the purpose of conveying information about current expectations and plans relating to the future and readers are cautioned that such statements may not be appropriate for other purposes. By its nature, this information is subject to inherent risks and uncertainties that may be general or specific and which give rise to the possibility that expectations, forecasts, predictions, projections or conclusions will not prove to be accurate, that assumptions may not be correct and that objectives, strategic goals and priorities will not be achieved. These risks and uncertainties include but are not limited those identified and reported in the Company’s public filings under the Company’s SEDAR profile at www.sedar.com. Although the Company has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking information, there may be other factors that cause actions, events or results not to be as anticipated, estimated or intended. There can be no assurance that such information will prove to be accurate as actual results and future events could differ materially from those anticipated in such statements. The Company disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise unless required by law.